Profound Medical Corp <PRN.TO>: Losses of 46  cents announced for fourth quarter

March 07, 2023 05:02 PM EST | By Reuters
Follow us on Google News:

7 March 2023 10:02 p.m. ​All figures in US dollars. The loss announced by Profound Medical Corp in the fourth quarter were lower than the Refinitiv mean estimate of losses. The company reported losses of -46 cents per share, 3 cents higher than the same quarter last year when the company reported EPS of -49 cents. Losses of -36 cents per share were anticipated by the five analysts providing estimates for the quarter. Wall Street expected results to range from -40 cents to -31 cents per share, with a forecasted mean of -36 cents per share. The company reported revenue of $1.26 million, which is lower than the estimated $2.72 million. RECOMMENDATIONS * The consensus recommendation for the company is "Buy". * The average consensus recommendation for the food retail & distribution peer group is also "Buy". FORECAST CHANGES * Three analysts are currently providing Refinitiv with estimates. * In the last week there have been no earnings estimate revisions by analysts covering the company. There was no change to the number of estimates. YEAR OVER YEAR * The company reported a fall in revenue to $1.26 million from $3.45 million in the same quarter last year.​ * Previous quarterly performance (using earnings preferred measure) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET, MISSED Oct. 31 2022 1.32​ 1.50 Beat Jul. 31 2022 1.62 1.77 Beat Apr. 30 2022 1.48 1.30 Missed​ Jan. 31 2022 1.50 1.53 Beat This summary was machine generated from Refinitiv data March 7 at 10:02 p.m.


The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK